​
​

Aldeyra Therapeutics (ALDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ALDX Stock Forecast

Aldeyra Therapeutics stock forecast is as follows: an average price target of $11.00 (represents a 128.69% upside from ALDX’s last price of $4.81) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

ALDX Price Target

The average price target for Aldeyra Therapeutics (ALDX) is $11.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $10.00. This represents a potential 128.69% upside from ALDX's last price of $4.81.

ALDX Analyst Ratings

Buy

According to 2 Wall Street analysts, Aldeyra Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ALDX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Aldeyra Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 03, 2024Justin KimOppenheimer--133.46%149.48%
Apr 03, 2024Justin KimOppenheimer--181.69%107.90%
Apr 02, 2024Matt CaufieldH.C. Wainwright--205.81%107.90%
Row per page
Go to

The latest Aldeyra Therapeutics stock forecast, released on Oct 03, 2024 by Justin Kim from Oppenheimer, set a price target of $12.00, which represents a 133.46% increase from the stock price at the time of the forecast ($5.14), and a 149.48% increase from ALDX last price ($4.81).

Aldeyra Therapeutics Price Target by Period

1M3M12M
# Anlaysts-13
Avg Price Target-$12.00$10.67
Last Closing Price$4.81$4.81$4.81
Upside/Downside-100.00%149.48%121.83%

In the current month, the average price target of Aldeyra Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aldeyra Therapeutics's last price of $4.81. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 03, 2024OppenheimerOutperformOutperformHold
Apr 03, 2024OppenheimerOutperformUpgrade
Jun 09, 2022CitigroupBuyBuyHold
Row per page
Go to

Aldeyra Therapeutics's last stock rating was published by Oppenheimer on Oct 03, 2024. The company gave ALDX a "Outperform" rating, the same as its previous rate.

Aldeyra Therapeutics Financial Forecast

Aldeyra Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 21
Revenue--------$392.62K-
Avg Forecast----$19.80M--$1.20M$3.00M$-46.00
High Forecast----$19.80M--$1.20M$3.00M$-46.00
Low Forecast----$19.80M--$1.20M$3.00M$-46.00
# Analysts----4--242
Surprise %--------0.13%-

Aldeyra Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $1.20M, with a low forecast of $1.20M, and a high forecast of $1.20M. ALDX's average Quarter revenue forecast represents a 205.64% increase compared to the company's last Quarter revenue of $392.62K (Dec 23).

Aldeyra Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 21
# Analysts----4--242
EBITDA--------$-13.97M$-15.31M
Avg Forecast----------
High Forecast----------
Low Forecast----------
Surprise %----------

undefined analysts predict ALDX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aldeyra Therapeutics's previous annual EBITDA (undefined) of $NaN.

Aldeyra Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 21
# Analysts----4--242
Net Income--------$-5.45M$-15.79M
Avg Forecast$-14.88M$-14.88M$-13.10M$-13.10M$-1.07M$-14.86M$-12.26M$-6.59M$-6.58M$-15.62M
High Forecast$-14.88M$-14.88M$-13.10M$-13.10M$-806.20K$-14.86M$-12.26M$-6.59M$-5.64M$-15.62M
Low Forecast$-14.88M$-14.88M$-13.10M$-13.10M$-1.25M$-14.86M$-12.26M$-6.59M$-6.89M$-15.62M
Surprise %--------0.83%1.01%

Aldeyra Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Aldeyra Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 21
# Analysts----4--242
SG&A--------$1.80M$2.55M
Avg Forecast----------
High Forecast----------
Low Forecast----------
Surprise %----------

Aldeyra Therapeutics's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ALDX last annual SG&A of $1.80M (Dec 23).

Aldeyra Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 21
# Analysts----4--242
EPS--------$-0.09$-0.27
Avg Forecast$-0.25$-0.25$-0.22$-0.22$-0.02$-0.25$-0.21$-0.11$-0.11$-0.26
High Forecast$-0.25$-0.25$-0.22$-0.22$-0.01$-0.25$-0.21$-0.11$-0.09$-0.26
Low Forecast$-0.25$-0.25$-0.22$-0.22$-0.02$-0.25$-0.21$-0.11$-0.12$-0.26
Surprise %--------0.84%1.03%

According to undefined Wall Street analysts, Aldeyra Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALDX previous annual EPS of $NaN (undefined).

Aldeyra Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals--891.89%Buy
LXRXLexicon Pharmaceuticals--679.22%Buy
INZYInozyme Pharma--445.35%Buy
GPCRStructure Therapeutics--206.98%Buy
DAWNDay One Biopharmaceuticals--190.85%Buy
LYRALyra Therapeutics--177.78%Hold
PHATPhathom Pharmaceuticals--173.33%Buy
ETNB89bio--162.53%Buy
CGEMCullinan Oncology--157.77%Buy
TERNTerns Pharmaceuticals--149.56%Buy
ALDXAldeyra Therapeutics--128.69%Buy
VRDNViridian Therapeutics--93.27%Buy
MCRBSeres Therapeutics--71.23%Buy
ARDXArdelyx--70.90%Buy
IBRXImmunityBio--58.73%Buy
TARSTarsus Pharmaceuticals--33.62%Buy
HOOKHOOKIPA Pharma--30.43%Buy
ETONEton Pharmaceuticals--20.93%Buy
TVTXTravere Therapeutics--19.11%Buy
BPMCBlueprint Medicines--13.55%Buy

ALDX Forecast FAQ

Is Aldeyra Therapeutics a good buy?

Yes, according to 2 Wall Street analysts, Aldeyra Therapeutics (ALDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ALDX's total ratings.

What is ALDX's price target?

Aldeyra Therapeutics (ALDX) average price target is $11 with a range of $10 to $12, implying a 128.69% from its last price of $4.81. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Aldeyra Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ALDX stock, the company can go up by 128.69% (from the last price of $4.81 to the average price target of $11), up by 149.48% based on the highest stock price target, and up by 107.90% based on the lowest stock price target.

Can Aldeyra Therapeutics stock reach $7?

ALDX's average twelve months analyst stock price target of $11 supports the claim that Aldeyra Therapeutics can reach $7 in the near future.

What are Aldeyra Therapeutics's analysts' financial forecasts?

Aldeyra Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $21M (high $21M, low $21M), average EBITDA is $0 (high $0, low $0), average net income is $-34.773M (high $-34.504M, low $-34.952M), average SG&A $0 (high $0, low $0), and average EPS is $-0.585 (high $-0.58, low $-0.588). ALDX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-55.958M (high $-55.958M, low $-55.958M), average SG&A $0 (high $0, low $0), and average EPS is $-0.94 (high $-0.94, low $-0.94).

Did the ALDX's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Dec 2023), Aldeyra Therapeutics's revenue was $392.62K, missing the average analysts' forecast of $3M by -86.91%. The company's EBITDA was $-13.975M, beating the average prediction of $0 by 0%. Aldeyra Therapeutics's net income was $-5.449M, missing the average estimation of $-6.579M by -17.18%. The company's SG&A was $1.8M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-0.0924, missing the average prediction of $-0.111 by -16.40%